Aerosol for treating plateau pulmonary edema and preparation method thereof

By preparing core-shell nanoparticle aerosols and using magnesium alginate to coat ceramide kinase and rhodioloside, ceramide-1-phosphate can be generated in situ, solving the problem of treating high-altitude pulmonary edema. This significantly reduces pulmonary edema symptoms and microvascular permeability, and improves alveolar cell tolerance to hypoxia.

CN119015224APending Publication Date: 2024-11-26NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411128313.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing technologies are ineffective in treating high-altitude pulmonary edema because rapid descent is inconvenient and other methods are not very effective.

Method used

The aerosol, which uses core-shell nanoparticles, encapsulates ceramide kinase nanoparticles with magnesium alginate, and combines rhodioloside and ceramide-1-phosphate to achieve in-situ long-term release, enhances the lung's adaptability to low pressure and low oxygen, and reduces symptoms of pulmonary edema.

Benefits of technology

Aerosols can penetrate deep into the alveoli, generating ceramide-1-phosphate in situ, neutralizing oxidative stress, protecting lung tissue, significantly reducing pulmonary edema symptoms and microvascular permeability, and improving alveolar cell tolerance to hypoxia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015224A_ABST
    Figure CN119015224A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicaments, and discloses an aerosol for treating plateau pulmonary edema and a preparation method thereof. According to the preparation method, ceramide kinase (CREK) is entrapped by magnesium alginate-disodium adenosine triphosphate nanoparticles, then a CREK substrate ceramide (Cer), a rhodiola rosea extract (Rho) and polydopamine (PDA) are jointly entrapped to finally obtain core-shell nanoparticles, and the core-shell nanoparticles are prepared into an aerosol dosage form. When the aerosol is used for treating plateau pulmonary edema, the core-shell nanoparticles can penetrate into pulmonary alveolus parts due to small particle sizes, so that salidroside (Sa 1) and ceramide-1-phosphoric acid (C1P) are released in situ for a long time, and the aerosol is used for enhancing lung low-pressure and low-oxygen adaptability, weakening oxidative stress caused by low-pressure and low-oxygen and protecting lung tissues so as to relieve pulmonary edema symptoms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicaments, and in particular to an aerosol for treating high altitude pulmonary edema and a preparation method thereof. Background Art

[0002] High-altitude pulmonary edema (HAPE) is a severe acute high-altitude disease. It refers to a serious life-threatening disease caused by increased oxygen consumption due to people entering the plateau too quickly or exercising vigorously after entering the plateau. It is a high-permeability pulmonary edema of non-cardiogenic origin, with an acute onset, rapid progression, and great harm. If not treated in time, it may be life-threatening. Generally, patients are healthy individuals who are not adapted to the plateau. Scientific research has revealed its pathophysiological changes as well as diagnosis, prevention and treatment methods, but its cause is still not very clear.

[0003] HAPE is an idiopathic disease caused by compensatory disorders due to the body's inability to adapt to the low-pressure and hypoxic environment of the plateau when entering the plateau quickly. The exact cause of HAPE is unknown. A large number of studies have shown that its pathogenesis is complex and difficult to explain with a single mechanism. Several studies have proposed several hypotheses to explain the mechanism of HAPE's origin. At present, the focus is mainly on the changes in pulmonary microvessels, changes in active factors in lung tissue, changes in water channel proteins, and changes in alveolar fluid clearance.

[0004] Rapid recovery is the rule for the treatment of HAPE. Clinical studies have established that lowering the altitude is the best measure to improve HAPE symptoms and enable patients to fully recover. However, rapid descent to altitude is not always convenient and feasible, and other methods of treatment are not very effective. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide an aerosol for treating high-altitude pulmonary edema and a preparation method thereof. When the aerosol is used to treat high-altitude pulmonary edema, the core-shell nanoparticles can penetrate into the alveolar area to achieve in situ long-term release of salidroside (Sal) and ceramide-1-phosphate (C1P), so as to enhance the adaptability of the lungs to low pressure and low oxygen, reduce the oxidative stress caused by low pressure and low oxygen, protect the lung tissue and thus alleviate the symptoms of pulmonary edema.

[0006] In order to solve the above technical problems, the present invention provides a method for preparing an aerosol for treating high altitude pulmonary edema, comprising the following steps:

[0007] S1. Add sodium alginate to water, stir well to mix, and then add ceramide kinase and adenosine triphosphate disodium in sequence to obtain a first mixed solution;

[0008] S2. slowly adding the first mixed solution to the mixed solution of magnesium chloride and polyvinyl pyrrolidone by electrospraying, and then slowly dropping a saturated calcium chloride solution and anhydrous ethanol in sequence, overnight, centrifuging, washing with ethanol, and freeze-drying to obtain magnesium alginate-coated ceramide kinase nanoparticles;

[0009] S3. Dissolve ceramide, Rhodiola rosea extract and dopamine hydrochloride in water, stir and mix thoroughly to homogenize, then add the magnesium alginate-coated ceramide kinase nanoparticles, adjust the pH to 9.5-10.0, continue stirring for 10-12 hours, centrifuge, wash with water, centrifuge again, resuspend the precipitate with PBS solution to obtain a resuspended solution, add glycerol and dimethyl ether to obtain an aerosol for treating high-altitude pulmonary edema.

[0010] Preferably, the precipitate is resuspended with a PBS solution in a ratio of 50 mg to (20-50) ml.

[0011] Preferably, in step S1, in the first mixed solution, the feeding ratio of sodium alginate, ceramide kinase, disodium adenosine triphosphate and water is (0.18-0.20) g: (10-40) mg: (20-50) mg: 10 ml.

[0012] Preferably, in step S2, the dosage ratio of the first mixed solution, the mixed solution of magnesium chloride and polyvinyl pyrrolidone, the saturated calcium chloride solution and anhydrous ethanol is 10 ml: (50-75) ml: (1.2-2.0) ml: (250-500) ml.

[0013] Preferably, in the mixed solution of magnesium chloride and polyvinyl pyrrolidone, the concentration of magnesium chloride is 8-10 g / L, and the concentration of polyvinyl pyrrolidone is 10-12 g / L.

[0014] Preferably, in step S2, the feeding ratio of the ceramide, rhodiola rosea extract, dopamine hydrochloride, water and the magnesium alginate-coated ceramide kinase nanoparticles is (43.0-53.7) mg: (40-50) mg: (30.3-37.9) mg: 10 ml: (20-25) mg.

[0015] Preferably, in step S2, the weight average molecular weight of the polyvinyl pyrrolidone is 10,000-40,000.

[0016] Preferably, in step S2, the electrospraying method is specifically as follows: the first mixed solution is loaded into a syringe and electrosprayed from top to bottom through a capillary, the collecting roller is wrapped with a polypropylene non-woven fabric, and the lower edge of the collecting roller is immersed in the mixed solution of magnesium chloride and polyvinyl pyrrolidone; the electrospraying voltage is 20-30 kV, the receiving distance is 12-15 cm, the flow rate is 0.5-1.0 ml / h, and the collecting roller speed is 40-60 rpm.

[0017] Preferably, in step S3, adjusting the pH to 9.5-10.0 is specifically performed by dropwise adding 40-50 w / v% sodium hydroxide solution until the solution pH is 9.5-10.0.

[0018] Preferably, in step S3, the usage ratio of the resuspension solution, glycerol and dimethyl ether is 100 ml: (3-5) g: (20-25) g.

[0019] The present invention also provides an aerosol prepared by the above preparation method for treating high altitude pulmonary edema.

[0020] Compared with the prior art, the present invention encapsulates ceramide kinase (CREK) through magnesium alginate-adenosine disodium triphosphate nanoparticles, and then uses CREK substrate ceramide (Cer), rhodiola rosea extract (Rho) and polydopamine (PDA) to jointly encapsulate to finally obtain core-shell nanoparticles, and prepare them into an aerosol dosage form, which has the following technical effects:

[0021] (1) Magnesium alginate nanoparticles are used to construct a ceramide kinase immobilized enzyme system. Due to the small particle size, after the aerosol enters the respiratory tract, it can be smoothly deposited in the deep lungs, that is, the alveoli. In the alveoli, the nanoparticles use the Mg in the core of the core-shell nanoparticles to 2+ and Ca in the core-shell gap 2+ The reaction system of ceramide kinase is completed, with the core disodium adenosine triphosphate and the shell Cer as substrates, producing C1P in situ. This substance can reduce mitochondrial damage caused by HAPE, neutralize excessive oxidative stress, and ultimately relieve HAPE symptoms.

[0022] (2) The polydopamine shell of the nanoparticles also binds more salidroside, the main active ingredient in rhodiola rosea extract, through hydrogen bonds, which is released in the alveoli for a long time and can improve the tolerance of alveolar cells to hypoxia. C1P and Sal work together to more effectively protect lung tissue from HAPE. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a scanning electron microscope photograph of the freeze-dried aerosol prepared in Example 1;

[0024] Figure 2is the lung water content measured in each group in the animal experiment;

[0025] Figure 3 The Evans blue content in lung tissue of each group measured in the animal experiment;

[0026] Figure 4 is the malondialdehyde content in lung tissue of each group measured in the animal experiment;

[0027] Figure 5 These are the SOD and CAT activities in lung tissue of each group measured in the animal experiment. DETAILED DESCRIPTION

[0028] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples, but it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.

[0029] Extraction and purification of ceramide kinase:

[0030] The spleen of 8-week-old ICR mice was obtained, homogenized, and extracted with PBS solution at 4°C. The molecular weight cutoff range was 58,000-65,000 by gel column chromatography, and the crude ceramide kinase protein was obtained after lyophilization. The ceramide kinase reached 8.54 ng / mg using a mouse ceramide kinase (CERK) enzyme-linked immunosorbent assay (ELISA) kit.

[0031] Example 1

[0032] A method for preparing an aerosol for treating high altitude pulmonary edema comprises the following steps:

[0033] 1. Add 0.19g sodium alginate to 10ml water, stir and mix thoroughly, then add 30mg ceramide kinase and 40mg adenosine triphosphate disodium in sequence, put into syringe and spray from top to bottom through capillary, voltage 25kV, receiving distance 13cm, flow rate 0.7ml / h, collect roller wrapped with polypropylene non-woven fabric, speed 50rpm, the lower edge of the collecting roller is immersed in 70ml mixed solution containing 9g / L magnesium chloride and 11g / L polyvinyl pyrrolidone with weight average molecular weight of 25000, then slowly drip saturated calcium chloride solution into the mixed solution

[0034] 1.7 ml, then slowly add 380 ml of anhydrous ethanol, overnight, centrifuge, wash with ethanol, and freeze-dry to obtain magnesium alginate-coated ceramide kinase nanoparticles.

[0035] 2. Dissolve 50.2 mg of ceramide, 45 mg of Rhodiola rosea extract and 36.5 mg of dopamine hydrochloride in 10 ml of water, stir and mix thoroughly, then add 24 mg of the nanoparticles prepared in step 1, then add 48 w / v% sodium hydroxide solution until the solution pH is 9.8, continue stirring for 11 hours, centrifuge, wash with water, and centrifuge again. After resuspending the obtained precipitate with 45 ml of PBS solution per 50 mg of the precipitate, add 4.0 w / v% glycerol and 23 w / v% dimethyl ether to obtain an aerosol for treating high altitude pulmonary edema. Scanning electron microscopy shows that after freeze-drying, Figure 1 .

[0036] Example 2

[0037] A method for preparing an aerosol for treating high altitude pulmonary edema comprises the following steps:

[0038] 1. Add 0.18g sodium alginate to 10ml water, stir and mix thoroughly, then add 10mg ceramide kinase and 20mg adenosine triphosphate disodium in sequence, put into syringe and spray from top to bottom through capillary, voltage 20kV, receiving distance 12cm, flow rate 0.5ml / h, collect roller wrapped with polypropylene non-woven fabric, speed 40rpm, the lower edge of the collecting roller is immersed in 50ml mixed solution containing 8g / L magnesium chloride and 10g / L polyvinyl pyrrolidone with weight average molecular weight 10000, then slowly drip saturated calcium chloride solution into the mixed solution

[0039] 1.2 ml, then slowly add 250 ml of anhydrous ethanol, overnight, centrifuge, wash with ethanol, and freeze-dry to obtain magnesium alginate-coated ceramide kinase nanoparticles.

[0040] 2. Dissolve 43 mg of ceramide, 40 mg of Rhodiola rosea extract and 30.3 mg of dopamine hydrochloride in 10 ml of water, stir well to mix and homogenize, then add 20 mg of the nanoparticles prepared in step 1, then add 40 w / v% sodium hydroxide solution dropwise to the solution pH 9.5, continue stirring for 10 hours, centrifuge, wash with water, and centrifuge again to obtain a precipitate. After resuspending 50 mg of the precipitate with 20 ml of PBS solution, add 3.0 w / v% glycerol and 20 w / v% dimethyl ether to obtain an aerosol for the treatment of high-altitude pulmonary edema.

[0041] Example 3

[0042] A method for preparing an aerosol for treating high altitude pulmonary edema comprises the following steps:

[0043] 1. Add 0.2g sodium alginate to 10ml water, stir and mix thoroughly, then add 40mg ceramide kinase and 50mg adenosine triphosphate disodium in sequence, put into a syringe and spray from top to bottom through a capillary, the voltage is 30kV, the receiving distance is 15cm, the flow rate is 1ml / h, the collecting roller is wrapped with polypropylene non-woven fabric, the speed is 60rpm, the lower edge of the collecting roller is immersed in 75ml of a mixed solution containing 10g / L magnesium chloride and 12g / L polyvinyl pyrrolidone with a weight average molecular weight of 40000, then slowly drip 2.0ml of saturated calcium chloride solution into the mixed solution, and then slowly drip 500ml of anhydrous ethanol, overnight, centrifuge, wash with ethanol, and freeze-dry to obtain magnesium alginate-coated ceramide kinase nanoparticles.

[0044] 2. Dissolve 53.7 mg of ceramide, 50 mg of Rhodiola rosea extract and 37.9 mg of dopamine hydrochloride in 10 ml of water, stir well to mix and homogenize, then add 25 mg of the nanoparticles prepared in step 1, then add 50 w / v% sodium hydroxide solution dropwise until the solution pH is 10, continue stirring for 12 hours, centrifuge, wash with water, and centrifuge again to obtain a precipitate. After resuspending 50 mg of the precipitate with 50 ml of PBS solution, add 5.0 w / v% glycerol and 25 w / v% dimethyl ether to obtain an aerosol for treating high-altitude pulmonary edema.

[0045] Comparative Example 1 (no core)

[0046] A method for preparing an aerosol comprises the following steps:

[0047] 50.2 mg of ceramide, 45 mg of Rhodiola rosea extract, 30 mg of ceramide kinase, 40 mg of adenosine disodium triphosphate and 36.5 mg of dopamine hydrochloride were dissolved in 10 ml of water, stirred thoroughly to mix and homogenize, then 48 w / v% sodium hydroxide solution was added dropwise until the solution had a pH of 9.8, the mixture was stirred for 11 h, centrifuged, washed with water, and centrifuged again to obtain a precipitate. After resuspending 50 mg of the precipitate with 45 ml of PBS solution, 4.0 w / v% glycerol and 23 w / v% dimethyl ether were added to obtain an aerosol.

[0048] Comparative Example 2 (Non-migration Diffusion)

[0049] A method for preparing an aerosol comprises the following steps:

[0050] 1. Add 0.19g sodium alginate to 10ml water, stir and mix thoroughly, then add 30mg ceramide kinase, 50.2mg ceramide, 45mg rhodiola rosea extract and 40mg adenosine disodium triphosphate in sequence, put into a syringe and spray from top to bottom through a capillary, the voltage is 25kV, the receiving distance is 13cm, the flow rate is 0.7ml / h, the collecting roller is wrapped with a polypropylene non-woven fabric, the speed is 50rpm, the lower edge of the collecting roller is immersed in 70ml of a mixed solution containing 9g / L magnesium chloride and 11g / L polyvinyl pyrrolidone with a weight average molecular weight of 25000, then slowly drip 1.7ml of saturated calcium chloride solution into the mixed solution, and then slowly drip 380ml of anhydrous ethanol, overnight, centrifuge, wash with ethanol, and freeze-dry to obtain magnesium alginate-coated ceramide kinase nanoparticles.

[0051] 2. Add 36.5 mg of dopamine hydrochloride and 24 mg of the nanoparticles prepared in step 1 to 10 ml of water, stir thoroughly to mix and homogenize, then add 48 w / v% sodium hydroxide solution dropwise to a solution pH of 9.8, continue stirring for 11 h, centrifuge, wash with water, and centrifuge again to obtain a precipitate. After resuspending 50 mg of the precipitate with 45 ml of PBS solution, add 4.0 w / v% glycerol and 23 w / v% dimethyl ether to obtain an aerosol.

[0052] Comparative Example 3 (without nanoparticle structure)

[0053] A method for preparing an aerosol comprises the following steps:

[0054] 30 mg of ceramide kinase, 40 mg of adenosine disodium triphosphate, 50.2 mg of ceramide and 45 mg of Rhodiola rosea extract were dissolved in 45 ml of PBS solution, and 4.0 w / v % of glycerol and 23 w / v % of dimethyl ether were added to obtain an aerosol.

[0055] Animal experiments

[0056] Healthy male SPF Wistar rats were used to construct a high altitude pulmonary edema model, and the oxygen partial pressure at an altitude of 6000m was simulated for the experiment. The aerosol administration of Examples 1-3 and Comparative Examples 1-3 was tested, at 50ul / time / rat, once in the morning and evening each day. The plain was used as a blank, and the control group was used without administration. After 7 days, the water content of lung tissue, pulmonary microvascular permeability (Evans blue), and the malondialdehyde (MDA) content of lung tissue, superoxide dismutase (SOD) activity, and catalase (CAT) activity were tested. The results are shown in Table 1. Figure 2-Figure 5 .

[0057] Depend on Figure 2-Figure 5It can be seen that the aerosol prepared by the embodiment of the present invention can reduce the water content of lung tissue and weaken the permeability of lung microvessels. At the same time, it is found that the MDA content in the lung tissue of rats treated with Examples 1-3 is reduced, and the SOD activity and CAT activity are significantly increased. The aerosol prepared by Comparative Examples 1-3 can only slightly reduce the water content of the lung and weaken the permeability of lung microvessels, but the effect is far less than that of the embodiment. Moreover, the aerosol prepared by Comparative Examples 1-3 has no obvious effect on reducing mitochondrial damage caused by HAPE and neutralizing excessive oxidative stress, and the ability to inhibit lipid peroxidation is insufficient. Comparative Example 1 does not have a core of magnesium alginate, which affects the activity of ceramide kinase and also affects the sustained release effect. Because ceramide kinase, disodium adenosine triphosphate and ceramide are directly mixed in water during the preparation process, a large amount of C1P is produced and wrapped in polydopamine nanoparticles, and is directly released after entering the lungs. There is no diffusion process of ceramide from the shell to the core, and the drug half-life is short, which affects the therapeutic effect of HAPE. Comparative Example 2 has no polydopamine layer, only nanoparticles formed by magnesium alginate, and all reactants are mixed together, and the result is similar to that of Comparative Example 1. Comparative Example 3 has no controlled-release nanostructure, so the therapeutic effect of HAPE is not as good as the previous two.

[0058] The present invention provides an aerosol for treating high altitude pulmonary edema and a method for preparing the same. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be considered as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A method for preparing an aerosol for treating high altitude pulmonary edema, characterized in that: The steps include: S1. Add sodium alginate to water, stir well to mix, and then add ceramide kinase and adenosine triphosphate disodium to obtain a first mixed solution; S2. slowly adding the first mixed solution to the mixed solution of magnesium chloride and polyvinyl pyrrolidone by electrospraying, and then slowly dropping a saturated calcium chloride solution and anhydrous ethanol in sequence, overnight, centrifuging, washing with ethanol, and freeze-drying to obtain magnesium alginate-coated ceramide kinase nanoparticles; S3. Dissolve ceramide, Rhodiola rosea extract and dopamine hydrochloride in water, stir and mix thoroughly to homogenize, then add the magnesium alginate-coated ceramide kinase nanoparticles, adjust the pH to 9.5-10.0, continue stirring for 10-12 hours, centrifuge, wash with water, centrifuge again, resuspend the precipitate with PBS solution to obtain a resuspended solution, add glycerol and dimethyl ether to obtain an aerosol for treating high-altitude pulmonary edema.

2. The preparation method according to claim 1, characterized in that: In step S1, in the first mixed solution, the feeding ratio of sodium alginate, ceramide kinase, disodium adenosine triphosphate and water is (0.18-0.20) g: (10-40) mg: (20-50) mg: 10 ml.

3. The preparation method according to claim 2, characterized in that: In step S2, the dosage ratio of the first mixed solution, the mixed solution of magnesium chloride and polyvinyl pyrrolidone, the saturated calcium chloride solution and anhydrous ethanol is 10 ml: (50-75) ml: (1.2-2.0) ml: (250-500) ml.

4. The preparation method according to claim 3, characterized in that: In the mixed solution of magnesium chloride and polyvinyl pyrrolidone, the concentration of magnesium chloride is 8-10 g / L, and the concentration of polyvinyl pyrrolidone is 10-12 g / L.

5. The preparation method according to claim 3, characterized in that: In step S2, the feeding ratio of the ceramide, rhodiola rosea extract, dopamine hydrochloride, water and the magnesium alginate-coated ceramide kinase nanoparticles is (43.0-53.7) mg: (40-50) mg: (30.3-37.9) mg: 10 ml: (20-25) mg.

6. The preparation method according to claim 1, characterized in that: In step S2, the weight average molecular weight of the polyvinyl pyrrolidone is 10000-40000.

7. The preparation method according to claim 1, characterized in that: In step S2, the electrospraying method is specifically as follows: the first mixed solution is loaded into a syringe and electrosprayed from top to bottom through a capillary, the collecting roller is wrapped with a polypropylene non-woven fabric, and the lower edge of the collecting roller is immersed in the mixed solution of magnesium chloride and polyvinyl pyrrolidone; the electrospraying voltage is 20-30 kV, the receiving distance is 12-15 cm, the flow rate is 0.5-1.0 ml / h, and the collecting roller speed is 40-60 rpm.

8. The preparation method according to claim 1, characterized in that: In step S3, the pH value is adjusted to 9.5-10.0 by dropwise adding 40-50 w / v% sodium hydroxide solution until the pH value of the solution is 9.5-10.

0.

9. The preparation method according to claim 1, characterized in that: In step S3, the usage ratio of the resuspension solution, glycerol and dimethyl ether is 100 ml: (3-5) g: (20-25) g.

10. An aerosol for treating high altitude pulmonary edema prepared according to the preparation method according to any one of claims 1 to 9.